IGF1 and myocardial infarction: The hybrid hydrogel system can co-deliver 6-Bromoindirubin-3-oxime (BIO) and insulin-like growth factor 1 (IGF-1) to areas of myocardial infarction and thus improve cardiac function by promoting the proliferation of cardiomyocytes and revascularization.